News

Published on 23 May 2024 on GuruFocus.com via Yahoo Finance

Insider Sale: CEO Edward M. Kaye of Stoke Therapeutics Inc (STOK) Sells 42,350 Shares

Article preview image

On May 20, 2024, Edward M. Kaye, MD, Chief Executive Officer of Stoke Therapeutics Inc (NASDAQ:STOK), executed a significant stock transaction, selling 42,350 shares of the company. The transaction was filed on May 22, 2024, as detailed in the SEC Filing. The shares were sold at a price of $15.43 each, totaling approximately $653,420.55.

Warning! GuruFocus has detected 5 Warning Signs with STOK.

Read the rest of the article
NASDAQ.STOK price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
Biogen Strengthens Pipeline With Stoke Therapeutic's Dravet Syndrome Candidate...

On Tuesday, Biogen Inc. (NASDAQ:BIIB) and Stoke Therapeutics, Inc. (NASDAQ:STOK) collaborated to...

Benzinga · via Yahoo Finance 18 Feb 2025
Stoke and Biogen in pact for treatment for severe form of childhood epilepsy

Stoke will receive $165 million upfront and may get up to $385 million in milestone payments.

Market Watch 18 Feb 2025
Biogen Bets Up to $550 Million for Rights to Epilepsy Drug

Have a confidential tip for our reporters? Biogen Inc. has agreed to pay as much as $550 million ...

Bloomberg 18 Feb 2025
Biogen continues dealmaking buzz with Stoke Therapeutics - Boston Business...

Biogen Inc. is making good on its promise to focus on “external opportunities,” this time with a ...

The Business Journals 18 Feb 2025
The Zacks Analyst Blog Highlights ADMA Biologics, Tarsus Pharmaceuticals, Stoke...

For Immediate Release Chicago, IL – December 26, 2024 – Zacks.com announces the list of stocks...

Zacks · via Yahoo Finance 27 Dec 2024
Stoke Therapeutics, Inc (STOK): Pioneering RNA Medicine for Genetic Diseases

We recently published a list of 10 Small Cap Stocks with High Potential. In this article, we are...

Insider Monkey · via Yahoo Finance 9 Oct 2024
Insider Sale: CEO Edward M. Kaye of Stoke Therapeutics Inc (STOK) Sells 42,350 Shares

On May 20, 2024, Edward M. Kaye, MD, Chief Executive Officer of Stoke Therapeutics Inc (NASDAQ:ST...

GuruFocus.com via Yahoo Finance 23 May 2024
Stoke Therapeutics Inc (STOK) Reports Q1 2024 Financial Results: A Closer Look at Challenges ...

Revenue: Reported $4.2 million for Q1 2024, up from $5.2 million in Q1 2023, exceeding the estima...

GuruFocus.com via Yahoo Finance 8 May 2024
Stoke Therapeutics plans $75M public offering on heels of Dravet trial results - Boston Business...

With shares of Stoke Therapeutics Inc. trading at its highest level since October 2022, the biote...

The Business Journals 27 Mar 2024
Stoke Therapeutics (STOK) Up on Upbeat Dravet Syndrome Study Data

Stoke Therapeutics, Inc. STOK reported encouraging new data from two phase I/IIa studies and two ...

Zacks via Yahoo Finance 27 Mar 2024

Copyright Statfolio @ 2025

Social Accounts